Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$130.4 - $143.74 $4.3 Million - $4.74 Million
32,976 New
32,976 $4.55 Million
Q1 2023

May 15, 2023

BUY
$94.11 - $123.02 $12.4 Million - $16.3 Million
132,237 Added 434.33%
162,683 $16.5 Million
Q4 2022

Feb 14, 2023

BUY
$106.72 - $127.06 $3.25 Million - $3.87 Million
30,446 New
30,446 $3.64 Million
Q1 2022

May 16, 2022

SELL
$72.45 - $94.81 $764,564 - $1 Million
-10,553 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$79.65 - $106.22 $840,546 - $1.12 Million
10,553 New
10,553 $898,000
Q1 2021

May 17, 2021

SELL
$87.57 - $119.4 $6.92 Million - $9.44 Million
-79,044 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$86.91 - $108.33 $5.9 Million - $7.36 Million
-67,899 Reduced 46.21%
79,044 $7.58 Million
Q3 2020

Nov 16, 2020

BUY
$96.16 - $135.15 $14.1 Million - $19.9 Million
146,943 New
146,943 $14.1 Million
Q1 2020

May 15, 2020

SELL
$75.11 - $113.76 $330,108 - $499,975
-4,395 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$86.8 - $118.57 $5.4 Million - $7.37 Million
-62,171 Reduced 93.4%
4,395 $473,000
Q3 2019

Nov 14, 2019

BUY
$83.82 - $101.5 $5.58 Million - $6.76 Million
66,566 New
66,566 $6 Million
Q2 2019

Aug 14, 2019

SELL
$72.24 - $91.27 $27.1 Million - $34.2 Million
-375,076 Closed
0 $0
Q1 2019

May 14, 2019

SELL
$69.31 - $91.53 $23 Million - $30.4 Million
-332,399 Reduced 46.98%
375,076 $33 Million
Q4 2018

Feb 14, 2019

BUY
$68.32 - $124.36 $42.8 Million - $78 Million
626,995 Added 779.07%
707,475 $50.5 Million
Q3 2018

Nov 14, 2018

BUY
$98.88 - $125.85 $7.96 Million - $10.1 Million
80,480 New
80,480 $9.9 Million
Q2 2018

Aug 14, 2018

SELL
$75.3 - $105.99 $613,243 - $863,182
-8,144 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$75.88 - $92.43 $617,966 - $752,749
8,144 New
8,144 $675,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.